10:33 AM EDT, 03/14/2024 (MT Newswires) -- Axonics ( AXNX ) said Thursday that its R20 rechargeable sacral neuromodulation system has obtained CE Mark approval and that it expects to start selling to European customers in the middle of April.

The R20 cuts the number of times that patients with overactive bladder have to recharge their implanted neuromodulation device, Axonics ( AXNX ) said.

The company said that the R20 was approved in the US in January 2023 and in Canada in December 2022.

Price: 67.90, Change: +0.06, Percent Change: +0.09